In preclinical studies, caffeic acids and its analogues have also been reported to downregulate specificity protein 1 and IKZF1-IRF4-MYC axis in myeloma cells including cell lines resistant to immunomodulatory drugs lenalidomide and pomalidomide (88). This evidence concerns the gene IRF4 and plasma cell myeloma.